Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.

Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized
Colitis, Ulcerative
Colonoscopy
Double-Blind Method
Female
Gastrointestinal Agents
Humans
Maintenance Chemotherapy
Male
Middle Aged
Remission Induction
Severity of Illness Index
Symptom Flare Up
Young Adult

authors with profiles

Stephen B. Hanauer